References

• Barry M, Kell MR. Enhancing the adjuvant treatment of hormone receptor positive breast cancer. Breast J. 2009 Mar-Apr;15(2):194-8.
• Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-43.
• Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. Available at http://www.asco.org/ASCO/Downloads/Cancer%20Policy%20and%20Clinical%20Affairs/Clinical%20Affairs%20(derivative%20products)/AI/Unabridged%20AI%207.1.10.pdf. Accessed July 28, 2010.
• Dahl ML, Johansson I, Palmertz MP, et al. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther. 1992;51:12-17.
• Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-18.
• Flockhart D. CYP2D6 genotyping and the pharmacogenetics of tamoxifen. Clin Adv Hematol Oncol. 2008;6(7):493-4.
• Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239–48.
• Higgins MC, Rae JM, Flockhart DA, et al. Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing? J NCCN. 2009;7(2):203-13.
• Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005;5:6-13.
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer (v.1.2010). Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (free login required). Accessed May 26, 2010.
• Punglia RS, Burstein HJ, Winer EP, et al. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008;100(9):642-8.
• Sachse C, Brockmoller J, Bauer S, et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genetics. 1997; 60:284-95.
• Scroth WS, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429-36.
• Seruga B, Amir E. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat. 2010 Aug;122(3):609-17.
• Tamoxifen prescribing information. Available at http://www.drugs.com/pro/tamoxifen.html. Accessed May 26, 2010.
• U.S. Food and Drug Administration Website: Tamoxifen Background Summary. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4248B1-01-FDA-Tamoxifen%20Background%20Summary%20Final.pdf. Accessed July 14, 2009.
• Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology Clinical Practice Guideline: Update on the use of pharmacologic interventions Including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235-58.